Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features
<h3>Introduction</h3><p dir="ltr">Lymphoid enhancer-binding factor 1 (<i>LEF-1</i>) overexpression has been recently remarkably reported in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and has shown utility in distinguishing CLL/SLL from o...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , |
| Published: |
2020
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513566178017280 |
|---|---|
| author | Dina S. Soliman (14779333) |
| author2 | Einas Al‐Kuwari (14779336) Kodappully S Siveen (14779339) Rajaa Al‐Abdulla (14779342) Prem Chandra (9072038) Mohamed Yassin (4166515) Abdulqader Nashwan (14779345) Feryal A Hilmi (14779348) Ruba Y Taha (14779351) Zafar Nawaz (96166) Halima El‐Omri (14779354) Jericha M Mateo (14779357) Ahmad Al‐Sabbagh (14779360) |
| author2_role | author author author author author author author author author author author author |
| author_facet | Dina S. Soliman (14779333) Einas Al‐Kuwari (14779336) Kodappully S Siveen (14779339) Rajaa Al‐Abdulla (14779342) Prem Chandra (9072038) Mohamed Yassin (4166515) Abdulqader Nashwan (14779345) Feryal A Hilmi (14779348) Ruba Y Taha (14779351) Zafar Nawaz (96166) Halima El‐Omri (14779354) Jericha M Mateo (14779357) Ahmad Al‐Sabbagh (14779360) |
| author_role | author |
| dc.creator.none.fl_str_mv | Dina S. Soliman (14779333) Einas Al‐Kuwari (14779336) Kodappully S Siveen (14779339) Rajaa Al‐Abdulla (14779342) Prem Chandra (9072038) Mohamed Yassin (4166515) Abdulqader Nashwan (14779345) Feryal A Hilmi (14779348) Ruba Y Taha (14779351) Zafar Nawaz (96166) Halima El‐Omri (14779354) Jericha M Mateo (14779357) Ahmad Al‐Sabbagh (14779360) |
| dc.date.none.fl_str_mv | 2020-12-12T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1111/ijlh.13420 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Downregulation_of_Lymphoid_enhancer_binding_factor_1_i_LEF_1_i_expression_by_immunohistochemistry_and_flow_cytometry_in_chronic_Lymphocytic_Leukemia_with_atypical_immunophenotypic_and_cytologic_features/22258516 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis atypical CLL Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Flow cytometry Immunohistochemistry ymphoid enhancer-binding factor 1 (LEF-1) |
| dc.title.none.fl_str_mv | Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Introduction</h3><p dir="ltr">Lymphoid enhancer-binding factor 1 (<i>LEF-1</i>) overexpression has been recently remarkably reported in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and has shown utility in distinguishing CLL/SLL from other B-cell lymphomas. CLL has a well-defined immunophenotype, yet, some cases of CLL demonstrate atypical morphology/ phenotype reflected by low Matutes score (atypical CLL). Till date, <i>LEF1</i> expression has not been systematically studied in cases of CLL with atypical features.</p><h3>Methods</h3><p dir="ltr">In this study, <i>LEF-1</i> expression was assessed by two different techniques, (immunohistochemistry and flow cytometry), to investigate the expression profile of <i>LEF-1</i> in cases of CLL/SLL, in comparison with other low-grade B-lymphomas and CLL with atypical features, including atypical immunophenotype and CLL with increased prolymphocytes or morphologically atypical cells.</p><h3>Results</h3><p dir="ltr">We found that <i>LEF-1</i> expression is downregulated in CLL with atypical immunophenotype/features compared to classic CLL; Chi-Square <i>P</i> < .0001. The ratio for <i>LEF-1</i> expression in malignant B-cells/NK (by flow cytometry) in CLL/SLL with classic immunophenotype was higher than atypical CLL and is significantly higher in other small B-cell lymphomas (<i>P </i>< .01). Absence of <i>LEF-1</i> expression in CLL/SLL is correlated (<i>P</i> < .05) with downregulation of CD5, CD23, CD200, expression of FMC7, brighter expression of CD79b, brighter expression of surface light chain, increased prolymphocytes and lower Matutes score.</p><h3>Conclusion</h3><p dir="ltr">As downregulation of <i>LEF-1</i> expression is well correlated with atypical CLL, we suggest adding <i>LEF-1</i> to Matutes score as a beneficial marker to differentiate classic from atypical CLL <i>LEF-1</i> could also serve as a potential prognostic indicator for CLL clinical course.</p><h2>Other Information</h2><p dir="ltr">Published in: International Journal of Laboratory Hematology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1111/ijlh.13420" target="_blank">http://dx.doi.org/10.1111/ijlh.13420</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_7a9fe72ec07bd7164062ddd1eb675d06 |
| identifier_str_mv | 10.1111/ijlh.13420 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22258516 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic featuresDina S. Soliman (14779333)Einas Al‐Kuwari (14779336)Kodappully S Siveen (14779339)Rajaa Al‐Abdulla (14779342)Prem Chandra (9072038)Mohamed Yassin (4166515)Abdulqader Nashwan (14779345)Feryal A Hilmi (14779348)Ruba Y Taha (14779351)Zafar Nawaz (96166)Halima El‐Omri (14779354)Jericha M Mateo (14779357)Ahmad Al‐Sabbagh (14779360)Biomedical and clinical sciencesCardiovascular medicine and haematologyOncology and carcinogenesisatypical CLLChronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Flow cytometryImmunohistochemistryymphoid enhancer-binding factor 1 (LEF-1)<h3>Introduction</h3><p dir="ltr">Lymphoid enhancer-binding factor 1 (<i>LEF-1</i>) overexpression has been recently remarkably reported in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and has shown utility in distinguishing CLL/SLL from other B-cell lymphomas. CLL has a well-defined immunophenotype, yet, some cases of CLL demonstrate atypical morphology/ phenotype reflected by low Matutes score (atypical CLL). Till date, <i>LEF1</i> expression has not been systematically studied in cases of CLL with atypical features.</p><h3>Methods</h3><p dir="ltr">In this study, <i>LEF-1</i> expression was assessed by two different techniques, (immunohistochemistry and flow cytometry), to investigate the expression profile of <i>LEF-1</i> in cases of CLL/SLL, in comparison with other low-grade B-lymphomas and CLL with atypical features, including atypical immunophenotype and CLL with increased prolymphocytes or morphologically atypical cells.</p><h3>Results</h3><p dir="ltr">We found that <i>LEF-1</i> expression is downregulated in CLL with atypical immunophenotype/features compared to classic CLL; Chi-Square <i>P</i> < .0001. The ratio for <i>LEF-1</i> expression in malignant B-cells/NK (by flow cytometry) in CLL/SLL with classic immunophenotype was higher than atypical CLL and is significantly higher in other small B-cell lymphomas (<i>P </i>< .01). Absence of <i>LEF-1</i> expression in CLL/SLL is correlated (<i>P</i> < .05) with downregulation of CD5, CD23, CD200, expression of FMC7, brighter expression of CD79b, brighter expression of surface light chain, increased prolymphocytes and lower Matutes score.</p><h3>Conclusion</h3><p dir="ltr">As downregulation of <i>LEF-1</i> expression is well correlated with atypical CLL, we suggest adding <i>LEF-1</i> to Matutes score as a beneficial marker to differentiate classic from atypical CLL <i>LEF-1</i> could also serve as a potential prognostic indicator for CLL clinical course.</p><h2>Other Information</h2><p dir="ltr">Published in: International Journal of Laboratory Hematology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1111/ijlh.13420" target="_blank">http://dx.doi.org/10.1111/ijlh.13420</a></p>2020-12-12T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1111/ijlh.13420https://figshare.com/articles/journal_contribution/Downregulation_of_Lymphoid_enhancer_binding_factor_1_i_LEF_1_i_expression_by_immunohistochemistry_and_flow_cytometry_in_chronic_Lymphocytic_Leukemia_with_atypical_immunophenotypic_and_cytologic_features/22258516CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/222585162020-12-12T06:00:00Z |
| spellingShingle | Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features Dina S. Soliman (14779333) Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis atypical CLL Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Flow cytometry Immunohistochemistry ymphoid enhancer-binding factor 1 (LEF-1) |
| status_str | publishedVersion |
| title | Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features |
| title_full | Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features |
| title_fullStr | Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features |
| title_full_unstemmed | Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features |
| title_short | Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features |
| title_sort | Downregulation of Lymphoid enhancer‐binding factor 1 (<i>LEF‐1)</i> expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis atypical CLL Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Flow cytometry Immunohistochemistry ymphoid enhancer-binding factor 1 (LEF-1) |